Denmark · Delayed Price · Currency is DKK Zealand Pharma Earnings Call Transcripts
Fiscal Year 2026
-
The event highlighted a shift in obesity drug development toward metabolic health, with survodutide and petrelintide showing promising profiles for liver fat reduction and tolerability. Flexible dosing and patient adherence are central, with major trials and pipeline expansion underway.
-
The conference highlighted progress on the Metabolic Frontier 2030 strategy, with major clinical data for petrelintide and survodutide expected at ADA. Strong financial positioning, new research partnerships, and a focus on patient adherence and market expansion were emphasized.
-
Q1 2026 saw major clinical and financial milestones, including strong phase II and III results for obesity candidates, robust cash reserves, and the launch of a $200 million share buyback. Strategic partnerships and a focus on R&D underpin a positive outlook for 2026.
-
The discussion highlighted a robust pipeline targeting obesity and metabolic diseases, with Petrelintide showing strong efficacy and tolerability, and Survodutide poised for major phase III data this year. Strategic partnerships, financial strength, and upcoming clinical milestones position the company for significant growth.
-
The phase II ZUPREME-1 trial showed Petrelintide achieved sustained double-digit weight loss (8.7%-10.7%) with a placebo-like safety profile and minimal GI side effects. Efficacy was higher in women and EU participants, and the drug improved cardiovascular risk factors. Phase III trials are planned for late 2026.
-
Ambitious plans target obesity and metabolic diseases, with major clinical milestones for petrelintide and Survodutide expected in 2024. Strategic partnerships with Roche and Boehringer Ingelheim support a robust pipeline, aiming for five product launches in five years and significant investment in research.
Fiscal Year 2025
-
2025 saw record revenue and profit, driven by the Roche partnership and strong R&D investment. Key obesity and metabolic assets, petrelintide and survodutide, are advancing with major clinical milestones expected in 2026, supported by a robust cash position.
-
The company is transforming into a fully integrated biotech, focusing on novel obesity and metabolic health therapies, with petrelintide and survodutide as key assets. Major investments in research, strategic partnerships, and a robust pipeline aim for five launches and over 10 clinical candidates by 2030.
-
A novel obesity treatment strategy is being advanced through a key partnership, with petrelintide positioned for strong differentiation based on tolerability and efficacy. The company is leveraging its R&D strengths and capital to expand its pipeline and commercial presence, with major data readouts and strategic updates expected soon.
-
Strong progress in obesity drug pipeline with key phase 2 and 3 milestones, robust financials driven by Roche partnership, and a sharpened focus on high-impact assets. Guidance narrowed as dapiglutide development is paused, with significant cash reserves supporting future innovation.
-
A major partnership is advancing key assets toward late-stage trials, with a focus on obesity and rare diseases. Petrelintide is positioned for strong efficacy and tolerability, with flexible dosing strategies and a representative trial population. Regulatory and market trends favor double-digit weight loss and functional outcomes.
-
Ambitious growth in the obesity market is driven by differentiated amylin and GLP-1 assets, strategic partnership with Roche, and a focus on patient experience and adherence. Key clinical readouts and an R&D event are expected to shape the next phase of innovation and expansion.
-
Strong H1 2025 results driven by Roche partnership, with DKK 9.1B revenue and DKK 16.6B cash. Obesity pipeline advances with petrelintide and survodutide nearing key data, while robust financials support continued R&D and strategic partnerships.
-
Significant progress was made with Petrelintide, including a major partnership with Roche and expanded leadership to support growth. The company is advancing late-stage trials, targeting durable weight loss and differentiation in the obesity market, while maintaining a strong financial outlook.
-
A major partnership with Roche brings significant capital and shared development for obesity therapies, with petrelintide and other assets advancing through late-stage trials. The pipeline is robust, with key data and regulatory milestones expected over the next year.
-
Entered a transformative Roche partnership for petrelintide, securing strong financials and advancing a robust obesity pipeline. Key clinical milestones are expected in 2025–2026, with a focus on best-in-class therapies and long-term growth.
-
A major partnership was announced to co-develop and commercialize petrelintide for obesity, leveraging both companies' strengths. The agreement includes shared governance, 50/50 cost and profit splits in key markets, and plans for both monotherapy and combination therapies, with significant financial terms and global ambitions.
-
The presentation outlined a robust pipeline focused on differentiated obesity treatments, with petrelintide leading as a novel amylin analog targeting sustainable weight loss and improved tolerability. Significant clinical progress is expected this year, and partnering discussions are underway to support long-term growth.
Fiscal Year 2024
-
2024 saw major clinical and financial progress, with rapid advancement of obesity and rare disease pipelines, strong cash growth, and increased R&D investment. Key obesity assets entered pivotal trials, while partnership discussions for petrelintide remain ongoing.
-
Management highlighted stable hospital procedure volumes, robust cash flow, and a disciplined M&A approach. High growth portfolios are performing well, while UroLift faces office setting headwinds. The balloon pump market offers a near-term U.S. share gain opportunity.
-
Strong clinical progress in obesity and rare disease programs, with petrelintide and dapiglutide advancing to later-stage trials. Financials show robust cash reserves and increased R&D investment, supporting continued pipeline growth and commercial readiness.
-
Amylin-based therapies are emerging as promising, well-tolerated options for obesity, with petrelintide showing strong early efficacy and safety. Pipeline assets like dapiglutide and survodutide target additional mechanisms and indications, with multiple late-stage trials progressing.
-
Strong H1 2024 results highlighted by positive petrelintide obesity data, a record DKK 7B equity raise, and robust cash position. Expanded investment in obesity and rare disease pipelines, with key regulatory and clinical milestones ahead.
-
A 16-week Phase 1B trial of petrelintide showed up to 8.6% mean weight loss, a favorable safety profile, and mild GI side effects, supporting its potential as a differentiated alternative to GLP-1 therapies. A larger Phase 2B trial is planned for late 2024.
-
Upcoming phase I-B data for long-acting amylin is expected to show 7%-9% weight loss, with a focus on superior tolerability and muscle preservation. Strategic plans include advancing petrelintide and dapiglutide, strong rare disease pipeline progress, and a cash runway to 2027.
-
The event highlighted a robust obesity pipeline, with petrelintide showing strong early weight loss and tolerability, and plans for Phase IIb trials. Survodutide and dapiglutide offer differentiated mechanisms, while non-obesity assets near regulatory milestones and partnership discussions advance.